On March 4, it was reported that, Grifols, S.A. (NASDAQ:GRFS) said will pay an additional $12.5 million to finance and develop plasma products, to be sold by the Spanish company Source text for Eikon. On Thursday shares of Grifols, S.A. (NASDAQ:GRFS) closed at $32.39. Company’s EPS growth for next 5 years is recorded as 14.55%.
Seattle Genetics, Inc. (NASDAQ:SGEN)’s management presented at the following upcoming investor conference; Barclays Global Healthcare Conference on Wednesday, March 11, 8:30 a.m. Eastern Time, Miami. Seattle Genetics, Inc. (NASDAQ:SGEN) in last trading activity moved up 4.67% to close at $38.11. Company weekly performance is 7.05% while its quarterly performance stands at 7.78%. Seattle Genetics, Inc. (NASDAQ:SGEN) is -31.28% away from its 52 week high.
On March 2, Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) reported financial results for the fourth quarter and full year ended December 31, 2014. As of December 31, 2014, Intercept’s cash, cash equivalents and investment securities available for sale totaled approximately $239.7 million, compared to $144.8 million at December 31, 2013. On last trading day Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) fell -0.26% to close at $285.56. Its volatility for the week is 5.22% while volatility for the month is 5.31%. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) monthly performance is 44.47%.
On March 2, ReachLocal Inc (NASDAQ:RLOC), announced the appointments of Paras Maniar as its Chief Strategy Officer and Megan Opp as its Chief People Officer. The additions are instrumental in helping the company increase its focus on strategy and on developing and attracting the talent needed to achieve its long-term objectives. ReachLocal, Inc. (NASDAQ:RLOC) has 2.10% insider ownership while its institutional ownership stands at 78.40%. In last trading activity company’s stock closed at $3.07.
Bristol-Myers Squibb Company (NYSE:BMY) disclosed in a regulatory filing that its Chief Executive Officer Lamberto Andreotti received a 2014 total compensation that was about 30 percent higher than the prior year. Andreotti received a total compensation of $27.06 million, including base salary, stock grants and incentives in 2014, compared to the $20.85 million he received in 2013, and $17.20 million he got in 2012. On Thursday shares of Bristol-Myers Squibb Company (NYSE:BMY) closed at $66.65. Company’s sales growth for last 5 years was -3.30% and EPS growth for next 5 years is recorded as 16.21%.